Cisplatin Plus Etoposide in the Adjuvant Treatment of Patients with Non Small Cell Lung Cancer

Creative Commons License

Cubukcu E., Canhoroz M., Olmez O. F., Kanat O., Kurt E., Erol M., ...Daha Fazla

JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, cilt.5, sa.5, ss.414-416, 2014 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5 Sayı: 5
  • Basım Tarihi: 2014
  • Doi Numarası: 10.4328/jcam.1469
  • Dergi Adı: JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.414-416
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE) combination in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated. The disease-free survival was 10 (1-114) months and the median overall survival was 18 (3-114) months. Discussion: Based on our limited experience, we concluded that PE regimen is safe and effective as adjuvant therapy for patients with NSCLC.